{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:16:52Z","timestamp":1760314612439,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jclinepi.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T12:59:30Z","timestamp":1631105970000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Domperidone increases harmful cardiac events in Parkinson's disease: A Bayesian re-analysis of an observational study"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-578X","authenticated-orcid":false,"given":"Gis\u00e8le","family":"Nakhl\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8049-6875","authenticated-orcid":false,"given":"James M.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Renoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4059-3800","authenticated-orcid":false,"given":"Paul","family":"Khairy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"B\u00e9lisle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-6444","authenticated-orcid":false,"given":"Jacques","family":"LeLorier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2010","series-title":"Guidance for the use of Bayesian statistics in medical device clinical trials - Guidance for Industry and FDA Staff","author":"Campbell","key":"10.1016\/j.jclinepi.2021.09.002_bib0001"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0002","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/00031305.2019.1566091","article-title":"Inference and decision making for 21st-century drug development and approval","volume":"73","author":"Ruberg","year":"2019","journal-title":"The American Statistician"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0003","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/MLR.0b013e3181e24563","article-title":"Bayesian meta-analyses for comparative effectiveness and informing coverage decisions","author":"Berry","year":"2010","journal-title":"Medical care"},{"year":"2014","series-title":"Methods guide for effectiveness and comparative effectiveness reviews. AHRQ Publication No. 10(14)-EHC063-EF","key":"10.1016\/j.jclinepi.2021.09.002_bib0004"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0005","doi-asserted-by":"crossref","first-page":"206","DOI":"10.7326\/0003-4819-151-3-200908040-00126","article-title":"Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change","volume":"151","author":"Luce","year":"2009","journal-title":"Ann internal med"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0006","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/cer.13.73","article-title":"Bayesian data analysis in observational comparative effectiveness research: rationale and examples","volume":"2","author":"Olson","year":"2013","journal-title":"Journal of comparative effectiveness res"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0007","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/ije\/dyi312","article-title":"Bayesian perspectives for epidemiological research: I. Foundations and basic methods","volume":"35","author":"Greenland","year":"2006","journal-title":"Int j epidemiol"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0008","first-page":"e134","article-title":"CNODES: the Canadian network for observational drug effect studies","volume":"6","author":"Suissa","year":"2012","journal-title":"Open Med"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0009","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bcp.12964","article-title":"Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson\u2019s disease","volume":"82","author":"Renoux","year":"2016","journal-title":"Br j clin pharmacol"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40261-015-0360-0","article-title":"Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis","volume":"36","author":"Leelakanok","year":"2016","journal-title":"Clinical drug investigation"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0011","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/pds.3814","article-title":"Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case\u2013crossover study","volume":"24","author":"Chen","year":"2015","journal-title":"Pharmacoepidemiol and drug safety"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0012","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2125.2006.02722.x","article-title":"In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs","volume":"63","author":"De Bruin","year":"2007","journal-title":"Br j clin pharmacol"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0013","article-title":"Risk of out-of-hospital sudden cardiac death with use of domperidone, proton pump inhibitors, and metoclopramide: 358","volume":"23","author":"Arana","year":"2014","journal-title":"Pharmacoepidemiol and Drug Safety"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0014","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s40264-015-0338-0","article-title":"Risk of out-of-hospital sudden cardiac death in users of domperidone, proton pump inhibitors, or metoclopramide: a population-based nested case-control study","volume":"38","author":"Arana","year":"2015","journal-title":"Drug safety"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/pds.2016","article-title":"Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study","volume":"19","author":"Johannes","year":"2010","journal-title":"Pharmacoepidemiol and drug safety"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0016","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2125.2009.03496.x","article-title":"Sudden death in patients receiving drugs tending to prolong the QT interval","volume":"68","author":"Jolly","year":"2009","journal-title":"Br j clin pharmacol"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0017","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/eurheartj\/ehi312","article-title":"Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death","volume":"26","author":"Straus","year":"2005","journal-title":"Eur heart j"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0018","first-page":"885","article-title":"Ventricular arrhythmia and sudden unexpected death and domperidone","volume":"31","author":"van Noord","year":"2008","journal-title":"Drug Safety"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0019","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2165\/11536840-000000000-00000","article-title":"Domperidone and ventricular arrhythmia or sudden cardiac death","volume":"33","author":"van Noord","year":"2010","journal-title":"Drug safety"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1574886311308010009","article-title":"Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?","volume":"8","author":"Lertxundi","year":"2013","journal-title":"Current drug safety"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0021","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1161\/01.CIR.102.16.1883","article-title":"Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders","volume":"102","author":"Drolet","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc res"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0023","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"New England J Med"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0024","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/157488610791698334","article-title":"Domperidone and long QT syndrome","volume":"5","author":"Rossi","year":"2010","journal-title":"Current drug safety"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Statistics and computing"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0026","first-page":"581","article-title":"Markov chain monte carlo and gibbs sampling","author":"Carlo","year":"2004","journal-title":"Lecture notes for EEB"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0027","first-page":"473","article-title":"Practical markov chain monte carlo","author":"Geyer","year":"1992","journal-title":"Statistical science"},{"key":"10.1016\/j.jclinepi.2021.09.002_bib0028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pst.1595","article-title":"The current state of Bayesian methods in medical product development: survey results and recommendations from the DIA Bayesian Scientific Working Group","volume":"13","author":"Natanegara","year":"2014","journal-title":"Pharmaceutical statistics"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435621002821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435621002821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:21:12Z","timestamp":1760246472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435621002821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":28,"alternative-id":["S0895435621002821"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2021.09.002","relation":{},"ISSN":["0895-4356"],"issn-type":[{"type":"print","value":"0895-4356"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Domperidone increases harmful cardiac events in Parkinson's disease: A Bayesian re-analysis of an observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}